Clinical Trial Update: Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol T trial update reports testing vismodegib (GDC-0449) in cancers with SMO or PTCH1 mutations; the study is active but not recruiting an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Erivedge (vismodegib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-21